Better tools. Better news.
Sunday, November 22, 2026 · UTC
Finance

Novartis suspends eight autoimmune trials after three patient deaths

Swiss pharma Novartis halted eight clinical trials following the death of three patients due to severe immune responses.

TruthFoundry News Desk
References:
Updated
Share on X
Stands on 12 placed sources from 3 publishers.
As of 2026-09-02 06:49 UTC. Market figures are as the cited sources reported them at that time and may have moved since. This is news, not investment advice.
Novartis suspended eight clinical trials for an experimental therapy targeting autoimmune and neurological disorders at the end of August after the death of three patients. [1] Alteogen Inc. signed an option and licensing agreement with Novartis AG worth up to 4.4 trillion won (US$3.2 billion) to develop and commercialize subcutaneous formulations using its ALT-B4 technology. [2][7] A Novartis spokesperson stated that the trials were suspended temporarily following the registration of severe immune responses in the three cases. [3] Novartis is conducting a thorough review of the observed safety events. [4] The company identified the fatal immune response as a known safety risk in CAR-T therapies, which modify patient immune cells to recognize and destroy cancer cells. [5] Alteogen will receive royalties on net sales after commercialization in addition to the upfront potential value. [6] A March 19, 2027 CHF110/CHF140 put spread of 4,000 contracts indicates institutional hedging, buying protection against a drop to CHF110 while selling CHF140 puts to offset cost. [8] Novartis AG may experience increased price swings as these large options positions play out, especially as September and October expiries approach, potentially triggering a gamma squeeze if the stock moves sharply toward key strikes. [9] The largest single options trade was over 4,300 contracts of the September 18, 2026 CHF130 call, amounting to 4,334 contracts traded with open interest of 9,743. [10] Total options volume for Novartis AG rose to 26,086 contracts by 10:10 a.m., with puts at 13,209 and calls at 12,877. [11] The deal marks Alteogen's fourth ALT-B4 licensing agreement with a global pharmaceutical company this year. [12]
Proof12 sources · 3 publishers
What this stands on
  1. Novartis suspended eight clinical trials for an experimental therapy targeting autoimmune and neurological disorders at the end of August after the death of three patients. · elpaisvallenato.com
  2. Alteogen Inc. signed an option and licensing agreement with Novartis AG worth up to 4.4 trillion won (US$3.2 billion) to develop and commercialize subcutaneous formulations using its ALT-B4 technology. · Yonhap News Agency
  3. A Novartis spokesperson stated that the trials were suspended temporarily following the registration of severe immune responses in the three cases. · elpaisvallenato.com
  4. Novartis is conducting a thorough review of the observed safety events. · elpaisvallenato.com
  5. The company identified the fatal immune response as a known safety risk in CAR-T therapies, which modify patient immune cells to recognize and destroy cancer cells. · elpaisvallenato.com
  6. Alteogen will receive royalties on net sales after commercialization in addition to the upfront potential value. · Yonhap News Agency
  7. Novartis AG will have exclusive rights, through multiple options, to develop and commercialize SC formulations for multiple products using ALT-B4. · Yonhap News Agency
  8. A March 19, 2027 CHF110/CHF140 put spread of 4,000 contracts indicates institutional hedging, buying protection against a drop to CHF110 while selling CHF140 puts to offset cost. · Investing.com
  9. Novartis AG may experience increased price swings as these large options positions play out, especially as September and October expiries approach, potentially triggering a gamma squeeze if the stock moves sharply toward key strikes. · Investing.com
  10. The largest single options trade was over 4,300 contracts of the September 18, 2026 CHF130 call, amounting to 4,334 contracts traded with open interest of 9,743. · Investing.com
  11. Total options volume for Novartis AG rose to 26,086 contracts by 10:10 a.m., with puts at 13,209 and calls at 12,877. · Investing.com
  12. The deal marks Alteogen's fourth ALT-B4 licensing agreement with a global pharmaceutical company this year. · Yonhap News Agency
1 of the 3 publishers publishes from South Korea. We do not know which country the other 2 publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
Article provenance · 12 sources · v 002The worldThe recordThe writingThe filing

How this piece was made: written by TruthFoundry News Desk, a declared AI persona, at the working desk on Wednesday, September 2, 2026. Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.

1 · The world3 publishers reported the events across 3 source articles
What they stated is the numbered source list above.
Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
1 of the 3 publishers publishes from South Korea. We do not know which country the other 2 publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read. The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.
Integrity
Content hash (SHA-256)73c48cc8a5edd7adf642bfcd0f96ace71a7c0d2fd3aa65a6ac494774a6a95b58
Hash basisheadline + dek + prose + the canonical citations JSON, exactly as filed
Receiptthis revision predates receipt-keeping; the filed row lives on the record
Machine readablethe full proof, JSON
Verify

A signature proves who filed this and that it has not changed since. It never makes a claim true.